By David Wild
Originally published by our sister publication, Clinical Oncology News
Researchers at several centers across the country are raising doubts about rates of 30-day readmission after liver surgery for hepatocellular carcinoma as a quality metric.
In one study’s retrospective review of more than 16,000 patients who underwent liver transplantation or liver resection during a nearly 20-year period (Am Surg 2022;88[1]:83-92), researchers found 30-day readmissions were not associated